THE SIGNIFICANCE OF POST-PRANDIAL GLYCOSURIA IN THE TREATMENT OF DIABETES MELLITUS WITH PROTAMINE ZINC INSULIN
Authors: I. M. Rabinowitch
Journal: Annals of Internal Medicine (1939)

Article1 September 1939THE SIGNIFICANCE OF POST-PRANDIAL GLYCOSURIA IN THE TREATMENT OF DIABETES MELLITUS WITH PROTAMINE ZINC INSULINI. M. RABINOWITCH, F.A.C.P.I. M. RABINOWITCH, F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-13-3-385 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptProtamine zinc insulin is now a definitely established therapeutic agent for the treatment of diabetes mellitus. Judging from the literature, most of the difficulties which were met with, following our first reports1, 2, 3of the product now in general use†appear to have been overcome. Theoretically, protamine zinc insulin appeared to be. contraindicated in conditions for which quick action is necessary, though this also was contrary to our experiences. Coma is an example. Because of its slow action in ordinary amounts, it was repeatedly stated in the literature that protamine zinc insulin is contraindicated in coma. Actually, as...References1. RABINOWITCHFOSTERFOWLERCORCORAN IMJSAFAC: Clinical experiences with protamine zinc insulin and other mixtures of zinc and insulin in diabetes mellitus, Canad. Med. Assoc. Jr., 1936, xxxv, 239. Google Scholar2. RABINOWITCHFOWLERCORCORAN IMAFAC: Further observations on the use of protamine zinc insulin in diabetes mellitus, Canad. Med. Assoc. Jr., 1937, xxxv, 111. Google Scholar3. FOWLERBENSLEYRABINOWITCH AFEHIM: Control of diabetes mellitus with protamine zinc insulin in surgery, Canad. Med. Assoc. Jr., 1937, xxxvi, 561. Google Scholar4. RABINOWITCHFOWLERBENSLEY IMAFEH: The use of protamine zinc insulin in diabetic coma, Canad. Med. Assoc. Jr., 1937, xxxvii, 105. Google Scholar5. RABINOWITCH IM: The diagnosis of diabetes, Trans. Assoc. Life Ins. Med. Dir. N.A., 1933, xx, 9. Google Scholar6. FRANK E: Über experimentelle und klinische Glykosurien renalen Ursprungs, Arch. f. exper. Path. u. Pharmakol., 1913, lxxii, 387. CrossrefGoogle Scholar7. MOSENTHAL HO: Hyperglycaemia, Jr. Am. Med. Assoc, 1935, cv, 484. CrossrefGoogle Scholar8. WILDERWILBUR RMDL: Diseases of metabolism and nutrition, Arch. Int. Med., 1937, lix, 329. CrossrefGoogle Scholar9. SOSKINKATZSTROUSERUBINFELD SLNSSH: Treatment of elderly diabetic patients with cardiovascular disease, Arch. Int. Med., 1933, li, 122. CrossrefGoogle Scholar10. WIERZUCHOWSKI M: Oxidation of glucose as function of its supply, Jr. Physiol., 1937, xc, 440. CrossrefGoogle Scholar11. RABINOWITCH IM: The cholesterol content of the blood plasma as an index of progress in insulin-treated diabetics, Canad. Med. Assoc. Jr., 1927, xvii, 171. Google Scholar12. RABINOWITCH IM: The cholesterol content of blood plasma in diabetes mellitus, Arch. Int. Med., 1929, xliii, 363. CrossrefGoogle Scholar13. RABINOWITCH IM: The cholesterol content of blood plasma in juvenile diabetics, Arch. Int. Med., 1929, xliii, 372. CrossrefGoogle Scholar14. GRAY H: Lipoids in 1000 diabetic bloods, Am. Jr. Med. Sci., 1924, clxviii, 35. Google Scholar15. HUNT HM: Cholesterol in blood of diabetics treated at New England Deaconess Hospital, New England Jr. Med., 1929, cci, 659. CrossrefGoogle Scholar16. WHITEHUNT PH: Cholesterol of blood of diabetic children, New England Jr. Med., 1930, ccii, 607. CrossrefGoogle Scholar17. JOSLIN EP: Fat and the diabetic, New England Jr. Med., 1933, ccix, 519. CrossrefGoogle Scholar18. JOSLIN EP: Treatment of diabetes mellitus, 6th Ed., 1937, Lea and Febiger. Google Scholar19. MCEACHERNGILMOUR JMCR: Studies in cholesterol metabolism, Canad. Med. Assoc. Jr., 1932, xxvi, 30. Google Scholar20. RABINOWITCH IM: Diabetic gangrene, Canad. Med. Assoc. Jr., 1927, xvii, 27. Google Scholar21. RABINOWITCH IM: Experiences with high carbohydrate-low calorie diet for treatment of diabetes mellitus, Canad. Med. Assoc. Jr., 1930, xxiii, 489; New England Jr. Med., 1931, cciv, 799; Canad. Med. Assoc. Jr., 1932, xxvi, 141. Google Scholar22. RABINOWITCH IM: Arteriosclerosis in diabetes, ANN. INT. MED., 1935, viii, 1436. LinkGoogle Scholar23. HIMSWORTH HP: Protamine insulin and protamine zinc insulin in the treatment of diabetes mellitus, Brit. Med. Jr., 1937, i, 541. CrossrefGoogle Scholar24. WHITE P: Protamine insulin in the treatment of juvenile diabetes, South. Med. Jr., 1938, xxxi, 15. CrossrefGoogle Scholar25. WHITE P: Treatment of diabetic girls, Jr. Am. Med. Assoc, 1939, cxii, 1440. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Montreal, Canada*Received for publication August 16, 1938.From the Department of Metabolism, The Montreal General Hospital, Montreal, Canada.†Though attempts had been made by other workers to prolong the action of insulin and of Hagedorn's protamine insulin, the product upon which these reports were based was that first prepared by Scott and Fisher in the Connaught Laboratories, of the University of Toronto, and supplied to this hospital for clinical trial. It is the protamine zinc insulin which is now in general use. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 September 1939Volume 13, Issue 3Page: 385-393KeywordsClinical trial reportingComaDiabetes mellitusInsulinProtaminesZinc ePublished: 1 December 2008 Issue Published: 1 September 1939 Copyright & PermissionsCopyright, 1939, by The American College of PhysiciansPDF downloadLoading ...